Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.43 |
| ▸ | ECE1 | P42892 | 7/20 | 0.42 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051789 | 1.00 | MMP1 (0.43) | MMP1ECE1HTRA1TACR2ALDH1A1 | |
| SCHEMBL8067899 | 0.92 | MMP1 (0.41) | MMP1ECE1TACR2CTSLCTSB | |
| SCHEMBL8061343 | 0.91 | ECE1 (0.43) | ECE1 | |
| SCHEMBL6439631 | 0.90 | ECE1 (0.51) | MMP1ECE1 | |
| SCHEMBL8063600 | 0.86 | KMT2A (0.49) | ECE1 | |
| SCHEMBL8063587 | 0.84 | ECE1 (0.41) | ECE1TACR2 | |
| SCHEMBL8061347 | 0.84 | ECE1 (0.41) | ECE1TACR2 | |
| SCHEMBL8051791 | 0.84 | ECE1 (0.41) | ECE1TACR2 | |
| SCHEMBL8051794 | 0.84 | ECE1 (0.41) | ECE1TACR2 | |
| SCHEMBL5963487 | 0.82 | TACR2 (0.45) | MMP1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | claimed |
| WO-2005016249-A2 | COMPOSITIONS OF A CHROMENE OR PHENYL ACETIC ACID CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ACE INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | ACE, ACE2, AGTR2 | MMP1 82/4885ECE1 22/4885HTRA1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.